Jump to content

AstraZeneca share price rebounds following FY21 results update


Recommended Posts

In this article we review the AstraZeneca results and how the share price has reacted to the news.

bg_astrazeneca_336609093.jpgSource: Bloomberg
 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Thursday 10 February 2022 

AstraZeneca's fourth quarter (Q4) and full-year (FY) results have seen the group’s share price bucking the short-term sector trend as of late as it gains on the news.

A summary of the results is as follows:

  • Total revenue for the year increased by 41% to $37,417 million including COVID-19 vaccine revenues
  • Total Revenue for the year, excluding vaccines, increased 26% to $33,436m
  • Reported earnings per share (EPS) of $0.08 in FY21 vs $2.44 in FY20
  • Core EPS of $5.29 in FY21 vs $4.02 in FY20

FY22 outlook

AstraZeneca has provided the following in terms of the new financial year's outlook:

  • The majority of vaccine revenue in 2022 is expected to come from initial contracts
  • The Gross Profit Margin from the COVID-19 medicines is expected to be lower than the company average
  • Core Operating Expenses are expected to increase by a low-to-mid teens percentage, driven in substantial part by the full-year integration of Alexion expenses
  • Emerging Markets Total Revenue, including China, is expected to grow mid-single digits in FY 2022
  • China Total Revenue is expected to decline by a mid-single digit percentage in FY 2022, primarily due to continued NRDL and VBP programme impacting various medicines
  • The company remains confident in the longer term outlook for Emerging Markets, driven by a large market opportunity, broader patient access and an increased mix of new medicines

Comments on results

Double-digit growth across all of the group’s major jurisdictions, combined with the Alexion acquisition, has seen strong revenue growth for the group.

The reported drop in EPS (97%) reflects items related to the acquisition of Alexion, amortisation of intangibles, as well as impairments and restructuring charges.

The Core EPS figure, which omits the one-off items, highlights growth of around 32% in the group's primary operations.

While future earnings growth from COVID-19 products is expected to slow, the group is perhaps less reliant on these products than its peers, Pfizer and Moderna as a proportion of income and future growth.

Astrazeneca – technical analysis

AZ%201002.pngSource: IG charts

 

The share price of AstraZeneca has formed a sharp bullish price reversal near the 8120 level and from oversold territory. The reversal suggests 8860 and 8960 respectively as upside resistance targets from the move.

Traders looking to go long might consider using a close below 8120 as a stop-loss indication for the trade, although will need to assess whether the risk-to-reward is a favourable enough opportunity for the position.

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Posts

    • Sainsburys full year earnings and Unilever’s first quarter trading update both say the same thing, UK consumers are in for higher prices. The war in Ukraine, supply chain issues and the effects of ongoing Covid all to blame.      
    • US Dollar (DXY) Daily Price and Analysis US Q1 GDP may stall the greenback’s advance. A 20-year high nears for the US dollar. The multi-month US dollar rally continues with the greenback printing a fresh high today ahead of the first look at US Q1 GDP at 12.30 GMT. The US dollar basket (DXY) has been boosted by renewed weakness in the Euro and the Japanese Yen, as investors move from lower-yielding to higher-yielding currencies, while safe-haven flows continue to benefit the greenback. The US growth release later in the session is expected to show a sharp slowdown from the robust Q4 figure of 6.9%. The markets are currently pricing in growth of just 1% for the first three months of this year, with the slowdown mainly due to a reduction in inventory accrual over the quarter. This release is unlikely to move the greenback, unless there is a large miss or beat, as the Fed believe that 2022 US growth will be robust enough to let them tighten monetary policy sharply without damaging the economy. The latest US Core PCE data – the Fed’s preferred inflation reading – is released on Friday and this may have more effect on the US dollar than today’s GDP data. For all market moving economic data and events, see the DailyFX Calendar. The ongoing US dollar rally has been aided by weakness across a range of G7 currencies including the Euro, the Japanese Yen, and the British Pound. The Euro continues to battle with lowly growth expectations, exacerbated by energy concerns, the British Pound is mired by weak economic data, while the Japanese Yen is in freefall as the BoJ continues with its ultra-loose monetary policy.   The US dollar continues to press higher and looks set to break above 103.96, the March 2020 high. Above here the US dollar would be back at levels last seen nearly two decades ago. The March resistance will likely hold in the short-term, especially with month-end portfolio rebalancing at the end of the week, but US dollar strength is set to continue in the months ahead. USDOLLAR (DXY) WEEKLY PRICE CHART – APRIL 28, 2022 {{THE_FUNDAMENTALS_OF_BREAKOUT_TRADING}} What is your view on the US Dollar – bullish or bearish?   Apr 28, 2022 | DailyFX Nick Cawley, Strategist
    • While Tesla has nothing directly to do with Elon Musk buying Twitter - TSLA stock closed down 12% on news that Musk may have to sell stock and use other holdings to stand against the loan to finalise the purchase of the social media giant.        
×
×
  • Create New...